Agios Pharma (AGIO) Gets a Buy Rating from Needham
In a report released today, Chad Messer from Needham maintained a Buy rating on Agios Pharma (AGIO), with a price target of $69.00. The company’s shares closed last Monday at $35.45.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 11.2% and a 48.3% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Agios Pharma is a Strong Buy with an average price target of $69.83, a 96.7% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $73.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.75 and a one-year low of $27.77. Currently, Agios Pharma has an average volume of 645K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.